- Home
- ATAI vs LUNG Comparison
ATAI vs LUNG Comparison
Compare ATAI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- LUNG
- Stock Information
- Founded
- ATAI 2018
- LUNG 1995
- Country
- ATAI Netherlands
- LUNG United States
- Employees
- ATAI N/A
- LUNG N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- LUNG Industrial Specialties
- Sector
- ATAI Health Care
- LUNG Health Care
- Exchange
- ATAI Nasdaq
- LUNG Nasdaq
- Market Cap
- ATAI 1.6B
- LUNG 63.6M
- IPO Year
- ATAI 2021
- LUNG 2020
- Fundamental
- Price
- ATAI $3.88
- LUNG $1.66
- Analyst Decision
- ATAI Strong Buy
- LUNG Buy
- Analyst Count
- ATAI 5
- LUNG 7
- Target Price
- ATAI $14.00
- LUNG $6.81
- AVG Volume (30 Days)
- ATAI 5.0M
- LUNG 1.3M
- Earning Date
- ATAI 11-12-2025
- LUNG 11-12-2025
- Dividend Yield
- ATAI N/A
- LUNG N/A
- EPS Growth
- ATAI N/A
- LUNG N/A
- EPS
- ATAI N/A
- LUNG N/A
- Revenue
- ATAI $3,018,000.00
- LUNG $91,664,000.00
- Revenue This Year
- ATAI $736.04
- LUNG $10.41
- Revenue Next Year
- ATAI N/A
- LUNG $10.98
- P/E Ratio
- ATAI N/A
- LUNG N/A
- Revenue Growth
- ATAI 811.78
- LUNG 15.59
- 52 Week Low
- ATAI $1.15
- LUNG $1.31
- 52 Week High
- ATAI $6.75
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- ATAI 36.15
- LUNG 49.78
- Support Level
- ATAI $3.60
- LUNG $1.31
- Resistance Level
- ATAI $3.89
- LUNG $1.74
- Average True Range (ATR)
- ATAI 0.25
- LUNG 0.14
- MACD
- ATAI -0.02
- LUNG 0.00
- Stochastic Oscillator
- ATAI 26.79
- LUNG 40.63
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.